InsiderTrades

Form 4 for PCSA Processa Pharmaceuticals, Inc.

Accepted 2024-04-12 00:00:00 ET · period of report 2024-01-01 · accession 0000897069-24-000923 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2024-04-12 2024-01-01 PCSA Stanker James H CFO M - OptEx — +1,675 6,638 +34% —
D 2024-04-12 2024-01-01 PCSA Stanker James H CFO F - Tax $2.79 -518 6,120 -8% -$1,445
D 2024-04-12 2024-01-01 PCSA Stanker James H CFO M - OptEx $0.00 -1,675 24.0K -7% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2024-01-01 M A 1,675 — 6,638 D — — (F1) Distribution of vested restricted shares. (F2) Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.
2 Common Common Stock 2024-01-01 F D 518 $2.79 6,120 D — — (F2) Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.
3 Derivative Restricted Stock Units 2024-01-01 M D 1,675 $0.00 24,037 D $0.00 · — to — 1,675 Common Stock (F2) Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. (F1) Distribution of vested restricted shares.